Celsion Corp
Change company Symbol lookup
Select an option...
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
HLI Houlihan Lokey Inc
KICK Master Glazier's Karate International Inc
VIRT Virtu Financial Inc
FB Facebook Inc
ED Consolidated Edison Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Closing Price
$0.87
Day's Change
-0.03 (-3.33%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9199
Day's Low
0.854
Volume
(Light)
Volume:
3,060,855

10-day average volume:
4,281,050
3,060,855

COVID-19 Diagnostics Market Worth USD 8.04 Billion with Rise at 2.7% CAGR till 2027; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for R&D Activities: Fortune Business Insights(TM)

7:34 am ET October 26, 2020 (Globe Newswire) Print

The global COVID-19 diagnostics market size is projected to reach USD 8.04 billion by 2027, exhibiting a CAGR of 2.7% during the forecast period.

Uncontrolled spread of the coronavirus worldwide will be the major factor propelling the growth of this market, shares Fortune Business Insights(TM) in its report, titled "COVID-19 Diagnostics Market Size, Share & Industry Analysis, By Product (Instruments and Reagents & Kits), By Technology (PCR (Polymerase Chain Reaction), ELISA (Enzyme-linked Immunosorbent Assay), Point-of-care (POC), and Others), By Sample Type (Oropharyngeal and Nasopharyngeal Swabs, Blood, Urine, and Others), By End User (Hospitals & Clinics, Laboratories & Diagnostic Centers, Research Institutes, and Others), and Regional Forecast, 2020-2027".

According to Johns Hopkins University, global COVID-19 infections reached 100,000 in just 60 days, growing to 200,000 in the next 12-14 days, and the recent addition of 100,000 cases has taken only 3 days. The calculation of the spread of this disease is based on the estimation of the "reproduction number" or R Naught (Ro). The UK Research and Innovation organization states that if the Ro goes above 1, exponential growth will be witnessed.

As per a study published in the Journal of Clinical Medicine based on the virus transmission rate in Wuhan, the Ro was computed to be between 2.49 and 2.63. Such rapid transmission of the virus has surged the demand for coronavirus diagnostics tools and kits, which is boosting the growth of this market.

Inquire Before Buying: https://www.fortunebusinessinsights.com/enquiry/queries/covid-19-diagnostics-market-103291

The report states that the value of the global market stood at USD 6.22 billion in 2020 and also provides the following:

-- Detailed analysis of the short-term and long-term impact of the COVID-19 pandemic on the market;

-- Comprehensive insights into the upcoming opportunities in the market;

-- In-depth of the market, drivers, restraints, and segments; and

-- Careful examination of the regional developments, competitive landscape, and rising investment pockets for the market.

Concerted Efforts towards Developing COVID Detection Tests to Accelerate Growth

With the COVID-19 pandemic showing no signs of abatement, medical and regulatory bodies are collaborating to encourage innovation and speed up research in developing coronavirus detection tools.

For instance, in April 2020, the National Institutes of Health in the US announced the launch of Rapid Acceleration of Diagnostics (RADx) initiative with a funding of USD 1.5 billion to commercialize and widen the accessibility of COVID-19 testing.

Similarly, in June 2020, the US Food and Drug Administration (FDA) joined the COVID-19 Diagnostics Evidence Accelerator created by the Friends of Cancer Research and Reagan-Udall Foundation with the aim to evaluate the performance of PCR and antibody tests for COVID.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/covid-19-diagnostics-market-103291

High Number of COVID-19 Cases to Give North America Leading Market Position

The United States is one of the worst-hit countries in the world by the coronavirus pandemic, with the number of cases as of June 2020 standing at 2.68 million and 129,000 deaths. In response, the US government is injecting more funds into medical research facilities to accelerate development of COVID-19 diagnostics and widen the testing net in the country. The region's market size in 2020 stood at USD 2.20 billion.

In Europe, the virus is spreading at a furious pace, with the UK, Italy, Spain, France, and Germany having the highest number of cases. Quick adoption of advanced detection tools in the region will enable it to expand its footprint in the COVID-19 diagnostics market share in the immediate future. Heavy investments by governments in Asia Pacific in the healthcare sector are expected to favor market growth in the region.

Quick Buy - COVID-19 Diagnostics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/103291

Regulatory Support to Novel Diagnostic Solutions to Encourage Innovation

The coronavirus is tightening its hold on the world and pharmaceuticals and governments are in a race against time to develop and launch quick and accurate diagnostic tests for this deadly virus. As a result, bodies such as the FDA are providing the necessary support to companies by removing unnecessary regulatory barriers, which is encouraging other players to innovate.

Industry Developments:

-- May 2020: Sofia 2 SARS Antigen FIA test developed by Quidel was green lit by the FDA, making it the first antigen test approved in the US for the detection of COVID-19. These tests identify unique protein fragments found on the outer walls of the coronavirus and deliver quick results.

-- March 2020: The US FDA cleared Abbott's molecular point-of-care test for detection of COVID in patients through its Emergency Use Authorization (EUA). The test promises to deliver positive results in 5 minutes and negative results in 13 minutes.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/covid-19-diagnostics-market-103291

List of Key Players Covered in this COVID-19 Diagnostics Market Report:

-- PerkinElmer Inc. (Massachusetts, U.S)

-- Quest Diagnostics Incorporated (New Jersey, U.S)

-- Quidel Corporation (California, U.S)

-- Siemens Healthcare GmbH (Germany)

-- Abbott (Illinois, U.S)

-- Thermo Fisher Scientific Inc. (Massachusetts, U.S)

-- bioMerieux SA (France)

-- F. Hoffmann-La Roche Ltd (Switzerland)

-- Danaher Corporation (Washington D.C, U.S)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/covid-19-diagnostics-market-103291

COVID-19 Diagnostics Market Segmentations:

By Product

? Instruments

? Reagents & Kits

By Technology

? Polymerase Chain Reaction (PCR)

? Enzyme-linked Immunosorbent Assay (ELISA)

? Point-of-care (POC)

? Others

By Sample Type

? Oropharyngeal & Nasopharyngeal Swabs

? Blood

? Urine

? Others

By End User

? Hospital & Clinics

? Laboratories & Diagnostics Centers

? Research Institutes

? Others

By Geography

? North America (U.S. and Canada)

? Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

? Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

? Latin America (Brazil, Mexico, and Rest of Latin America)

? The Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

SECONDARY DATA SOURCES THAT WE REFER TO:

-- Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market

-- Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.

-- Website, reports, and press releases of end user facilities - Hospitals, Ambulatory Surgery Centres, Clinics

-- Industry journals and paid databases

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

-- Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies

-- Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.

-- Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility

-- Number of procedures and average price of procedures

-- Replacement rate and pricing of capital equipment

-- Market dynamics in relation to the market under focus - Drivers, restraints, trends, and opportunities

-- Market & technological trends, new product developments, product pipeline.

Have a Look at Related Reports:

In-vitro Diagnostics (IVD) Market Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 - 2026

Hepatitis C Drug Market Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026

Schizophrenia Drugs Market Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026

Molecular Diagnostics Market Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025

Digital Radiography Market Share and Global Trend By Product Type (Computed Radiography, Direct Digital Radiography), Application (General, Radiography Dentistry, Oncology, Orthopedic) End User (Hospital, Clinics, Diagnostic Centers) and Geography Forecast till 2026

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights(TM) Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights(TM)

LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-covid-19-diagnostics-market-10100

https://ml.globenewswire.com/media/05408ba1-26b1-4fdd-8f48-1af4df373348/small/fbi-logo-tm-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.